# Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

> **NCT01522547** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 12 (estimated)

## Conditions studied

- Anemia, Sickle Cell

## Interventions

- **DRUG:** pomalidomide

## Key facts

- **NCT ID:** NCT01522547
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-01
- **Primary completion:** 2012-10-01
- **Final completion:** 2013-12-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01522547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01522547, "Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01522547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*